FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220857524> ?p ?o ?g. }

• W4220857524 endingPage "109857" @default.
• W4220857524 startingPage "109857" @default.
• W4220857524 abstract "Inflammation is closely associated with atherosclerosis and plays a crucial role in the development of cardiovascular disease. Metformin sensitizes body cells to insulin, which may cause a reduction of atherogenic lipid fractions. Low neuregulin-4 (Nrg-4) levels, an adipokine, are linked to obesity, insulin resistance, impaired glucose tolerance and type 2 diabetes.We assessed the effect of oral supplementation with metformin on glycemic control, neuregulin-4 levels and carotid intima media thickness (CIMT) as a marker for subclinical atherosclerosis in adolescents with type 1 diabetes mellitus (T1DM) and microvascular complications.This randomized placebo-controlled trial included 80 type 1 diabetic patients with microvascular complications who were randomly divided to receive either 24 weeks of metformin 500 mg/day or matching placebo. Fasting blood glucose (FBG), HbA1c, C-reactive protein (CRP), urinary albumin creatinine ratio (UACR), lipid profile, Nrg-4 and CIMT were assessed at baseline and study end.Both groups were well-matched as regards baseline clinical and laboratory data (p greater than 0.05). After 24-weeks, metformin therapy for the intervention group resulted in a significant decrease of HbA1c, CRP, UACR, total cholesterol and CIMT while Nrg-4 levels were increased compared with baseline levels (p < 0.001) and with placebo group(p < 0.001). Baseline Nrg-4 levels were negatively correlated to FBG, HbA1c, total cholesterol, CRP and CIMT. Metformin was well-tolerated.Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis." @default.
• W4220857524 created "2022-04-03" @default.
• W4220857524 creator A5025725556 @default.
• W4220857524 creator A5061285748 @default.
• W4220857524 creator A5078536462 @default.
• W4220857524 date "2022-04-01" @default.
• W4220857524 modified "2023-09-30" @default.
• W4220857524 title "Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial" @default.
• W4220857524 cites W1526574240 @default.
• W4220857524 cites W1535828758 @default.
• W4220857524 cites W1550111394 @default.
• W4220857524 cites W1902765749 @default.
• W4220857524 cites W1965620761 @default.
• W4220857524 cites W2004922185 @default.
• W4220857524 cites W2006956325 @default.
• W4220857524 cites W2013524893 @default.
• W4220857524 cites W2032020948 @default.
• W4220857524 cites W2049103906 @default.
• W4220857524 cites W2053406877 @default.
• W4220857524 cites W2059669783 @default.
• W4220857524 cites W2062250486 @default.
• W4220857524 cites W2066467287 @default.
• W4220857524 cites W2093631945 @default.
• W4220857524 cites W2094941678 @default.
• W4220857524 cites W2103874678 @default.
• W4220857524 cites W2112246719 @default.
• W4220857524 cites W2113050462 @default.
• W4220857524 cites W2113506865 @default.
• W4220857524 cites W2114245735 @default.
• W4220857524 cites W2115110594 @default.
• W4220857524 cites W2115168238 @default.
• W4220857524 cites W2123826132 @default.
• W4220857524 cites W2130877223 @default.
• W4220857524 cites W2139311756 @default.
• W4220857524 cites W2139334262 @default.
• W4220857524 cites W2146901298 @default.
• W4220857524 cites W2150563156 @default.
• W4220857524 cites W2164994583 @default.
• W4220857524 cites W2170938622 @default.
• W4220857524 cites W2171294019 @default.
• W4220857524 cites W2188909866 @default.
• W4220857524 cites W2256255858 @default.
• W4220857524 cites W2336740776 @default.
• W4220857524 cites W2402511072 @default.
• W4220857524 cites W2416046640 @default.
• W4220857524 cites W2531490114 @default.
• W4220857524 cites W2531934030 @default.
• W4220857524 cites W2538762208 @default.
• W4220857524 cites W2608127355 @default.
• W4220857524 cites W2616226194 @default.
• W4220857524 cites W2616952314 @default.
• W4220857524 cites W2740802742 @default.
• W4220857524 cites W2753955810 @default.
• W4220857524 cites W2762525513 @default.
• W4220857524 cites W2800652755 @default.
• W4220857524 cites W2810597988 @default.
• W4220857524 cites W2891593039 @default.
• W4220857524 cites W2897316664 @default.
• W4220857524 cites W2915046128 @default.
• W4220857524 cites W2921000340 @default.
• W4220857524 cites W3113331434 @default.
• W4220857524 cites W3127598236 @default.
• W4220857524 cites W4235479662 @default.
• W4220857524 doi "https://doi.org/10.1016/j.diabres.2022.109857" @default.
• W4220857524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35351535" @default.
• W4220857524 hasPublicationYear "2022" @default.
• W4220857524 type Work @default.
• W4220857524 citedByCount "2" @default.
• W4220857524 countsByYear W42208575242022 @default.
• W4220857524 countsByYear W42208575242023 @default.
• W4220857524 crossrefType "journal-article" @default.
• W4220857524 hasAuthorship W4220857524A5025725556 @default.
• W4220857524 hasAuthorship W4220857524A5061285748 @default.
• W4220857524 hasAuthorship W4220857524A5078536462 @default.
• W4220857524 hasConcept C126322002 @default.
• W4220857524 hasConcept C134018914 @default.
• W4220857524 hasConcept C142724271 @default.
• W4220857524 hasConcept C168563851 @default.
• W4220857524 hasConcept C204787440 @default.
• W4220857524 hasConcept C27081682 @default.
• W4220857524 hasConcept C2776914184 @default.
• W4220857524 hasConcept C2777180221 @default.
• W4220857524 hasConcept C2777391703 @default.
• W4220857524 hasConcept C2778096610 @default.
• W4220857524 hasConcept C2778270857 @default.
• W4220857524 hasConcept C2779306644 @default.
• W4220857524 hasConcept C2780323712 @default.
• W4220857524 hasConcept C2780473172 @default.
• W4220857524 hasConcept C2781195455 @default.
• W4220857524 hasConcept C2781203188 @default.
• W4220857524 hasConcept C555293320 @default.
• W4220857524 hasConcept C71924100 @default.
• W4220857524 hasConcept C90924648 @default.
• W4220857524 hasConceptScore W4220857524C126322002 @default.
• W4220857524 hasConceptScore W4220857524C134018914 @default.
• W4220857524 hasConceptScore W4220857524C142724271 @default.
• W4220857524 hasConceptScore W4220857524C168563851 @default.
• W4220857524 hasConceptScore W4220857524C204787440 @default.

• next